Literature DB >> 8353049

Depletion of circulating cyst(e)ine by oral and intravenous mesna.

B Stofer-Vogel1, T Cerny, A Küpfer, E Junker, B H Lauterburg.   

Abstract

The sulfhydryl status of normal and tumour cells is critically important in determining their susceptibility to various cytostatic agents. As a sulfhydryl compound, mesna (sodium 2-mercaptoethane-sulfonate) which is used in large doses to prevent haemorrhagic cystitis associated with certain chemotherapeutic regimens might derange cellular thiol homeostasis. In order to investigate the effects of mesna on the concentrations of thiols in plasma, cysteine, glutathione and their disulfides were measured by HPLC following the oral and intravenous administration of mesna to healthy volunteers. After 7.3 mmol mesna i.v. free cysteine rose from 8.2 (95% CI 7.0-9.4) nmol ml-1 to 53.6 (47.4-59.8) nmol ml-1 at 5 min, most likely due to reduction of circulating cystine by the sulfhydryl drug. This initial rise was followed by a marked decrease of total cyst(e)ine in plasma from 276 (215-337) nmol ml-1 to a nadir of 102 (89-115) nmol ml-1 between 30-120 min after infusion, most likely due to an increased uptake of cysteine into cells and an increased urinary excretion of cyst(e)ine. Qualitatively similar changes were seen after oral mesna. The present data indicate that mesna depletes circulating cyst(e)ine and may thereby markedly alter the sulfhydryl status of cells in vivo although the drug itself is not taken up by most cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353049      PMCID: PMC1968397          DOI: 10.1038/bjc.1993.391

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro.

Authors:  A T McGown; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine.

Authors:  R D Issels; A Nagele; K G Eckert; W Wilmanns
Journal:  Biochem Pharmacol       Date:  1988-03-01       Impact factor: 5.858

3.  The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents.

Authors:  L F Chasseaud
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

4.  Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.

Authors:  I C Shaw; M S Weeks
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

5.  Oral bioavailability of mesna tablets.

Authors:  B Stofer-Vogel; T Cerny; M Borner; B H Lauterburg
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine.

Authors:  S Aebi; R Assereto; B H Lauterburg
Journal:  Eur J Clin Invest       Date:  1991-02       Impact factor: 4.686

7.  Ethanol suppresses hepatic glutathione synthesis in rats in vivo.

Authors:  B H Lauterburg; S Davies; J R Mitchell
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

8.  Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.

Authors:  M S Jones; R D Murrell; I C Shaw
Journal:  Eur J Cancer Clin Oncol       Date:  1985-05

9.  2-Mercaptoethanesulfonate-cysteine disulfide excretion following the administration of 2-mercaptoethanesulfonate--a pitfall in the diagnosis of sulfite oxidase deficiency.

Authors:  M Duran; G Aarsen; R H Fokkens; N M Nibbering; B P Cats; P K de Bree; S K Wadman
Journal:  Clin Chim Acta       Date:  1981-03-19       Impact factor: 3.786

10.  Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.

Authors:  K Ormstad; S Orrenius; T Låstbom; N Uehara; J Pohl; J Stekar; N Brock
Journal:  Cancer Res       Date:  1983-01       Impact factor: 12.701

View more
  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

2.  Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

Authors:  Bradley L Urquhart; David J Freeman; Murray J Cutler; Rahul Mainra; J David Spence; Andrew A House
Journal:  Clin J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 8.237

3.  Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy.

Authors:  B H Lauterburg; T Nguyen; B Hartmann; E Junker; A Küpfer; T Cerny
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.